Non-Dihydropyridine: Think Verapamil and Diltiazem. They act selectively on the myocardium. This will reduce oxygen demand of myocardial tissue. They have minimal systemic effect and are less likely to cause reflex tachycardia. REFERENCES. 1. Hockerman, G.H.; Peterson, B.Z.; Johnson, B.D.; Catterall, W.A. (1997).

2023年11月1日 · Calcium channel blockers (CCBs) are split into two categories, dihydropyridines (DHP), such as amlodipine and nicardipine, and non-dihydropyridines (non-DHP), such as verapamil and diltiazem.

Nondihydropyridine calcium channel blockers are a class of antiarrhythmic drugs used to treat tachydysrhythmias (abnormal cardiac rhythm with a rate greater than 100 beats per minute) and hypertension (high blood pressure).

Calcium channel blockers (CCBs) share a common mechanism of action. However, the manner in which they exert their pharmacological effects is different between subclasses. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) agents, whereas the latter have more marked negative inotropic effects.

2022年3月31日 · Rate control with beta-blockers or non-dihydropyridine calcium channel blockers (NDCC), which include diltiazem and verapamil, is preferred to digoxin or amiodarone due to their more rapid onset of action and effectiveness at modulating higher sympathetic tone.

Purpose: The 2021 European Society of Cardiology guidelines on acute and chronic heart failure (HF) recommend that non-dihydropyridine calcium channel blockers (NDCC) should be avoided in patients with HF with reduced ejection fraction. It also emphasizes that beta-blockers only be initiated in clinically stable, euvolemic patients.

Dual CCB produced a significantly greater reduction in SBP (21.6±9.2 mmHg) from baseline than DHP (10.3±6.3 mmHg (WMD = 10.9 mmHg, P < 0.0001)) or NDHP (8.9±4.2 mmHg (WMD = 14.1 mmHg, P = 0.002)). Dual CCB therapy reduced DBP from baseline more than either monotherapy (dual CCB = 17.5±10.2 mmHg vs. DHP = 11.6±8.7 mmHg, WMD = 5.5 mmHg, P ...

2013年1月15日 · Dual calcium-channel blocker (CCB) with a dihydropyridine (DHP) and a nondihydropyridine (NDHP) has been proposed for hypertension treatment. However, the safety and efficacy of this approach is not well known. A MEDLINE/EMBASE/CENTRAL search for randomized clinical trials published on this topic from 1966 to February 2012 was performed.

A calcium channel blocker used to treat hypertension and to manage chronic stable angina. A non-dihydropyridine calcium channel blocker used in the treatment of angina, arrhythmia, and hypertension.

2022年8月1日 · Non-vasodilating BBs are considered the first-line therapy. In the presence of intolerance or contraindications to BBs, non-dihydropyridine calcium channel blockers (NDH-CCB), such as verapamil and diltiazem, can be considered viable alternatives, with the caveat that their vasodilating properties can be a limitation to their use.